Your SlideShare is downloading. ×
New therapies for asthma 2013 Edward Omron MD, MPH
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

New therapies for asthma 2013 Edward Omron MD, MPH


Published on

A simple discussion of asthma for those individuals newly diagnosed, pregnancy and asthma, and difficult to treat asthmatics with new therapies 2013. This presentation is for non-health care …

A simple discussion of asthma for those individuals newly diagnosed, pregnancy and asthma, and difficult to treat asthmatics with new therapies 2013. This presentation is for non-health care professionals.

Edward Omron MD, MPH, FCCP
Pulmonary Medicine Specialist
Morgan Hill, CA 95037

Published in: Health & Medicine

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. Edward Omron MD, MPH, FCCPPulmonary, Critical Care, and Internal MedicineMorgan Hill, CA
  • 2.  Reversible inflammatory lung disease The airways of the lung are swollen andnarrowed resulting in “wheezing” Recurrent cough, chest tightness, shortnessof breath, and exercise limitation Symptoms worsen withexercise, infection, changes in weather, orat night. Can occur at any age or gender
  • 3. Beta2 receptors lie within airway smooth muscleAlbuterol causes the muscle to relax and the airway to dilate
  • 4.  In 2009, 25 million Americans had asthma◦ Of these 13 million have had an asthma attack In 2007 there were 3500 deaths fromasthma◦ 63% of these deaths occurred in women The prevalence of adult asthma in CA 2009is 8% Asthma accounts for 50 billion health caredollars yearly
  • 5.  Evidence of airway disease and an objectivemeasure of airway function i.e. spirometry Wheezing, cough, tightness, shortness ofbreath are commonly reported Just because you wheeze doesn’t mean youhave asthma!◦ A diagnosis of asthma may last a lifetime and mayhave unintended consequences!◦ May sure the clinician verifies the diagnosis beforeinitiating therapy
  • 6.  Pattern of symptoms◦ Episodic vs continual; seasonal◦ Onset, duration and frequency (weekly)◦ Diurnal variations (Nocturnal) Aggravating Factors◦ Environmental allergens(mold, dust-mite, cockroach)◦ Occupational chemicals Family History Nasal Polyps Runny nose/congestion/heartburn
  • 7.  Blood Tests◦ CBC with differential◦ IGE level in some patients Region 14 Respiratory Allergy Profile fornorthern California Allergic Asthma◦ Diagnose suspected IgE antibody-mediatedrespiratory reactions◦ This test includes total IgE and 23 ImmunoCapspecific IgE allergens◦ Bermuda grass, birch, cat epithelium anddander, cockroach, common ragweed, dustmite, dog dander, and mold (Alternariaalternata, Aspergillus fumigatus)
  • 8.  Asthma◦ Clinical Suspicion◦ Airway muscle spasm “hyperreactivity” All patients should undergo spirometry◦ Be careful of office based spirometry in primarycare offices!◦ Normal Spirometry does not exclude the diagnosis◦ Methacholine bronchoprovocation to confirm◦ Exercise challenge and testing in some cases
  • 9.  Not using medications correctly or unmotivated Diagnosis wrong or secondary diagnosis Secondary Gain steroid resistant Asthma phenotypes STOP SMOKING Approach◦ Repeat spirometry and peak flow log◦ Cardiopulmonary exercise testing◦ Bronchoscopy◦ High resolution CT of chest◦ Immunologic markers
  • 10.  Pulmonary Specialist Referral◦ Initially to confirm the diagnosis◦ ALWAYS after life threatening asthmatic attack◦ Exercise limitation not improving therapies◦ Pregnant patients with asthma◦ Other conditions complicate asthma(e.g., sinusitis, severe rhinitis, VCD, GERD)◦ Patient is being considered for immunotherapy◦ Occupational asthma evaluation
  • 11.  Most common potentially serious medicalproblem in pregnancy: 8% of pregnantwomen Higher risk of complications to includepreterm birth, low birth weight, congenitalmalformations, and perinatal death Pregnancy may affect the course of asthma Treatment reduces risk to both mother andinfant Choice of medications is key to preventadverse effects on the fetus
  • 12.  Shortness of breath in pregnancy◦ Normal as gestation evolves◦ Asthma, reflux, postnasaldrip, bronchitis, pulmonaryembolism, cardiomyopathy◦ NO smoking◦ Pregnancy class B medications Budesonide (inhaled steroid) Montelukast (leukotriene antagonist) Cromolyn puffer◦ Necessary pregnancy class C medication Albuterol inhaler or nebulized therapy
  • 13.  There is no cure of asthma thus far in 2013 CONFIRM the diagnosis before anyaugmentation of treatment of regimens◦ Rule out vocal cord dysfunction◦ Cystic fibrosis◦ Pertussis infection◦ Reflux disease◦ Interstitial Lung Diseases Severe persistent asthma is a great challengeto both the patient and the physician
  • 14.  Severe persistent asthmatics with allergiesand an elevated IgE antibody level IgE is an allergy antibody◦ It binds to allergens and causes the release ofinflammatory mediators which makes asthmaworse Xolair binds to IgE antibody and turns it off Reduced medication use, symptoms, andimproved quality of life Cost about $1500.00 monthly Monthly subcutaneous injections
  • 15.  Severe asthmatics have excessive smoothmuscle in the airways BT is a non-drug procedure that reducesairway smooth muscle by applying heat tothe airways◦ This reduces the frequency of asthma attacks Three outpatient procedures performedthree weeks apart under sedation
  • 16.  Severe exacerbations: 32% reduction Emergency Department Visits: 84%reduction Days missed from work or school: 1.3 vs3.9 days Asthma Quality of Life Score: BT 1.35 vs1.16 No significant adverse effects for up to 5years
  • 17.  FDA Indication: approved for the treatmentof severe persistent asthma in patients 18years or older whose asthma is not wellcontrolled on inhaled corticosteroids andlong acting beta agonists Exercise limitation persists despiteaggressive inhalational and oral therapeuticagents.
  • 18.  NEJM 2006;35:2689-2695 NEJM 2009; 360: 1002-1014 Am J Respir Crit Care Med 2012; 185: 709–714 Lancet 2012; 380: 651-659 NEJM 2009; 360: 1862-1869